Synapto Company Profile

Background

Overview

Synapto is an early-stage medical technology company focused on revolutionizing Alzheimer's diagnosis through the use of portable Electroencephalogram (EEG) devices combined with artificial intelligence (AI). Founded in 2017 and based in College Park, Maryland, Synapto aims to provide a more accessible, affordable, and objective method for diagnosing Alzheimer's disease, moving away from traditional neuroimaging techniques.

Mission and Vision

Synapto's mission is to enhance the early detection and diagnosis of Alzheimer's disease by developing innovative, portable EEG devices integrated with AI algorithms. The company's vision is to make Alzheimer's diagnosis universally accessible, thereby improving patient outcomes through timely intervention.

Primary Area of Focus

Synapto specializes in the development of portable EEG devices that utilize AI to analyze brain activity patterns associated with Alzheimer's disease. This approach aims to provide a non-invasive, cost-effective, and efficient diagnostic tool for healthcare providers.

Industry Significance

Alzheimer's disease is the sixth leading cause of death in the United States, affecting nearly 44 million people worldwide. Traditional diagnostic methods, such as neuroimaging, are often expensive and not universally accessible. Synapto's innovative approach has the potential to transform Alzheimer's diagnosis by offering a more practical and widespread solution.

Key Strategic Focus

Core Objectives

• Innovation in Diagnostics: Develop and commercialize portable EEG devices integrated with AI to facilitate early and accurate Alzheimer's diagnosis.

• Accessibility: Ensure that diagnostic tools are affordable and accessible to a broad range of healthcare providers and patients.

• Regulatory Approval: Obtain necessary regulatory approvals, including FDA clearance, to bring products to market.

Specific Areas of Specialization

• Portable EEG Technology: Design and manufacture compact EEG devices suitable for widespread use in various healthcare settings.

• AI Integration: Develop AI algorithms capable of analyzing EEG data to identify biomarkers associated with Alzheimer's disease.

Key Technologies Utilized

• Electroencephalography (EEG): A non-invasive method to record electrical activity of the brain, used as the primary data collection tool.

• Artificial Intelligence (AI): Machine learning algorithms employed to interpret complex EEG data and detect patterns indicative of Alzheimer's disease.

Primary Markets Targeted

• Healthcare Providers: Hospitals, clinics, and diagnostic centers seeking efficient and cost-effective diagnostic tools.

• Research Institutions: Organizations conducting studies on Alzheimer's disease and related neurological disorders.

Financials and Funding

Funding History

As of the latest available information, Synapto has secured funding through various competitions and grants, including winning first place in the National Institutes of Health’s DEBUT competition. The company is actively seeking additional funding to support product development and regulatory approval processes.

Total Funds Raised

Specific details regarding the total funds raised by Synapto are not publicly disclosed.

Notable Investors

Information about individual investors is not publicly available.

Intended Utilization of Capital

The capital raised is intended to support the following areas:

• Product Development: Enhancing the design and functionality of portable EEG devices.

• Regulatory Approvals: Navigating the FDA clearance process to bring products to market.

• Market Expansion: Scaling operations to reach a broader customer base.

Pipeline Development

Key Pipeline Candidates

• Portable EEG Device: A compact, user-friendly EEG device integrated with AI algorithms for Alzheimer's diagnosis.

Stages of Development

• Prototype Development: Initial prototypes have been developed and are undergoing testing.

• Clinical Validation: Plans are in place to conduct clinical trials to validate the device's efficacy in diagnosing Alzheimer's disease.

Target Conditions

• Alzheimer's Disease: The primary condition targeted by Synapto's diagnostic device.

Anticipated Milestones

• FDA Clearance: Achieving FDA clearance under the 510(k) Class 2 Medical Device Pathway.

• Market Launch: Introduction of the device to healthcare providers and research institutions.

Technological Platform and Innovation

Proprietary Technologies

• Synapto EEG Device: A portable EEG device designed for easy use in various healthcare settings.

• AI Diagnostic Algorithm: Proprietary machine learning algorithms developed to analyze EEG data for Alzheimer's biomarkers.

Significant Scientific Methods

• EEG Signal Processing: Techniques for capturing and processing brain electrical activity.

• Machine Learning: Algorithms trained to detect patterns in EEG data associated with Alzheimer's disease.

Leadership Team

Key Executives

• Dhruv Patel: Co-founder and CEO. Dhruv is a graduate of the A. James Clark School of Engineering at the University of Maryland and has been instrumental in developing Synapto's technology and business strategy.

Competitor Profile

Market Insights and Dynamics

The Alzheimer's diagnostic market is evolving, with a growing emphasis on non-invasive and cost-effective diagnostic tools. Synapto's approach aligns with this trend, offering a solution that could potentially transform the diagnostic landscape.

Competitor Analysis

Synapto operates in a competitive landscape with several companies focusing on Alzheimer's diagnostics and related technologies. Notable competitors include:

• NeuroKaire: Develops neurotechnology solutions for neurological disorders.

• Seer: Specializes in proteomics.